Oxyquinoline

Oxyquinoline

SCHEMBL5166047

Cc1cc(B(O)c2ccc(C#N)cc2)ccc1Cl.Oc1cccc2cccnc12

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.44
METAP1 P53582 2/20 0.44
MMP2 P08253 1/20 0.44
CHRM1 P11229 1/20 0.44
TSHR P16473 1/20 0.44
COMT P21964 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 4/20 0.40
ALOX12 P18054 2/20 0.40
EGLN1 Q9GZT9 2/20 0.37
GLO1 Q04760 2/20 0.36
LMNA P02545 3/20 0.36
SLC40A1 Q9NP59 1/20 0.35
PKM P14618 1/20 0.35
MAPT P10636 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyquinoline SCHEMBL5166115 0.93 METAP2 (0.43) METAP2METAP1MMP2CHRM1TSHR
Oxyquinoline SCHEMBL5163996 0.86 MMP2 (0.47) METAP2METAP1MMP2CHRM1TSHR
Oxyquinoline SCHEMBL5166153 0.82 MMP2 (0.47) METAP2METAP1MMP2CHRM1TSHR
SCHEMBL5166054 0.77 GAA (0.50) ALDH1A1NPSR1POLBGAAKDM4E
Oxyquinoline SCHEMBL5167712 0.75 MMP2 (0.44) METAP2METAP1MMP2CHRM1TSHR
Oxyquinoline SCHEMBL5168551 0.74 MMP2 (0.51) METAP2METAP1MMP2CHRM1TSHR
Oxyquinoline SCHEMBL5167257 0.74 MMP2 (0.48) METAP2METAP1MMP2CHRM1TSHR
Oxyquinoline SCHEMBL5165569 0.73 METAP2 (0.49) METAP2METAP1MMP2CHRM1TSHR
SCHEMBL5166117 0.72 GAA (0.49) ALDH1A1NPSR1POLBGAAKDM4E
Oxyquinoline SCHEMBL27805579 0.71 TSHR (0.66) METAP2METAP1MMP2CHRM1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771182-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES Anacor Pharmaceuticals, Inc. (US) 2007-04-11 EP disclosed
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes ANACOR PHARMACEUTICALS, INC. 2006-01-19 US disclosed
WO-2005123095-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES ANACOR PHARMACEUTICALS, INC. (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes BPGM, HRH1, HRH3 METAP2 1098/4885METAP1 908/4885MMP2 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.